PTO/SB/05 (03-01) Approved for use through 10/31/2002, OMB 0651-0032 Please type a plus sign (+) inside this box ----U.S. Patent and Trademark Office; U.S. DEPARIMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. UTILITY CL001177DIV2 Attorney Docket No. PATENT APPLICATION Gennady V. MERKULOV First Inventor TRANSMITTAL ISOLATED HUMAN METALLOPROTEASE. Title ហ្វេ -(Only for new nonprovisional applications under 37 CFR 1.53(b)) Express Mail Label No. Assistant Commissioner for Patents **APPLICATION ELEMENTS** ADDRESS TO: Box Patent Application See MPEP chapter 600 concerning utility patent application contents. Washington, DC 20231 Fee Transmittal Form (e.g., PTO/SB/17) CD-ROM or CD-R in duplicate, large table or (Submit an original and a duplicate for fee processing) Computer Program (Appendix) Applicant claims small entity status. 8. Nucleotide and/or Amino Acid Sequence Submission See 37 CFR 1.27. (if applicable, all necessary) opecinication [Total Pages (preferred arrangement set forth below) 3. [X] X Computer Readable Form (CRF) - Descriptive title of the invention b. Specification Sequence Listing on: - Cross Reference to Related Applications CD-ROM or CD-R (2 copies); or Statement Regarding Fed sponsored R & D - Reference to sequence listing, a table, (11 pages) ii. 🔼 paper or a computer program listing appendix c. X Statements verifying identity of above copies - Background of the Invention - Brief Summary of the Invention ACCOMPANYING APPLICATION PARTS - Brief Description of the Drawings (if filed) - Detailed Description Assignment Papers (cover sheet & document(s)) 9. - Claim(s) 37 CFR 3.73(b) Statement Power of - Abstract of the Disclosure 10 (when there is an assignee) Attorney 11. English Translation Document (if applicable) X Drawing(s) (35 U.S.C. 113) [ Total Sheets

[ Total Pages 5. Oath or Declaration Newly executed (original or copy) Copy from a prior application (37 CFR 1.63 (d)) a.

> **DELETION OF INVENTOR(S)** Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR

1.63(d)(2) and 1.33(b).

of in an Application Data Sheet under 37 CFR 1.76:

IX b.

Continuation

==Prior application information:

Washington, DC 20231

7

ndi.

[X](3 pages) 6. Application Data Sheet, See 37 CFR 1.76

Divisional

Examiner

(for continuation/divisional with Box 18 completed)

Copies of IDS Information Disclosure 12. Citations Statement (IDS)/PTO-1449 Preliminary Amendment 13 Return Receipt Postcard (MPEP 503) 14. (Should be specifically itemized) Certified Copy of Priority Document(s) (if foreign priority is claimed) 15 Nonpublication Request under 35 U.S.C. 122 16. (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent. 17. Other: 18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment,

09

1652

of prior application No.:

Group Art Unit

920,048

For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts. 19. CORRESPONDENCE ADDRESS

Continuation-in-part (CIP)

C. L. Fronda

Customer Number or Bar Code Label Name <u>Address</u> City State Zip Code Country Telephone

Lin Sun-Hoffman, Ph.D., Reg No. 47,983 Registration No. (Attorney/Agent) Name (Print/Type) Dec 14, 2001 Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC

20231 DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO: Assistant Commissioner for Patents, Box Patent Application,

PTO/SB/17 (10-01)
Approved for use through 10/31/2002, OMB 0651 0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it displays a valid OMB control number.

F	E	E	T	R	Α	N	S	M		T	T	Α	L
			fo	r	F	Υ	2	00	1	2			

Under the Paperwork Reduction Act of 1999	5, no persons are required to	u.s. Patent and 110 respond to a collection of info	idemark Office; U.S. DEPARTMENT OF COMMERC Imation unless it displays a valid OMB control numbe				
<b>FEE TRANS</b>		Complete if Known					
I LL INANS	MILLIAL	Application Number					
for FY 2	2002	Filing Date	December 14, 2001 Gennady V. MERKULOV				
101112	.002	First Named Inventor					
Patent fees are subject to a	nnual revision	Examiner Name					
		Group Art Unit					
OTAL AMOUNT OF PAYMENT	(\$) 1046	Attorney Docket No.	CL001177DIV2				

METHOU OF PAYMENT	FEE CALCULATION (continued)								
The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to:	3. ADDITIONAL FEES								
Deposit	Large Small								
Account Number 50-0970	Entity Entity Fee	Ena Daid							
Deposit Account Celera Genomics	Code (\$) Code (\$) Fee Description	Fee Paid							
Account Name Celera Genomics	105 130 205 65 Surcharge - late filing fee or oath								
Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17	127 50 227 25 Surcharge - late provisional filing fee or cover sheet								
Applicant claims small entity status.	139 130 139 130 Non-English specification								
See 37 CFR 1.27  2. Payment Enclosed:	147 2,520 147 2,520 For filing a request for ex parte reexamination	}							
2. Payment Enclosed: Check Credit card Money Order Other	112 920* 112 920* Requesting publication of SIR prior to Examiner action								
FEE CALCULATION	113 1,840* 113 1,840* Requesting publication of SIR after Examiner action								
41. BASIC FILING FEE	115 110 215 55 Extension for reply within first month								
Large Entity Small Entity	116 400 216 200 Extension for reply within second month								
Fee Fee Fee Fee Pee Description Code (\$) Code (\$) Fee Paid	117 920 217 460 Extension for reply within third month								
101 740 201 270 Hills, Events	118 1,440 218 720 Extension for reply within fourth month								
	128 1,960 228 980 Extension for reply within fifth month								
= 106 330 206 165 Design filing fee 107 510 207 255 Plant filing fee 108 740 208 370 Reissue filing fee	119 320 219 160 Notice of Appeal								
108 740 208 370 Reissue filing fee	120 320 220 160 Filing a brief in support of an appeal								
114 160 214 80 Provisional filing fee	121 280 221 140 Request for oral hearing								
SUPTOTAL (4) (P)	138 1,510 138 1,510 Petition to institute a public use proceeding								
SUBTOTAL (1) (\$) 740	140 110 240 55 Petition to revive - unavoidable								
2. EXTRA CLAIM FEES	141 1,280 241 640 Petition to revive - unintentional								
Extra Claims below Fee Paid	142 1,280 242 640 Utility issue fee (or reissue)								
Independent	143 460 243 230 Design issue fee								
	144 620 244 310 Plant issue fee								
multiple Dependent 270 = 0	122 130 122 130 Petitions to the Commissioner								
Large Entity Small Entity	123 50 123 50 Processing fee under 37 CFR 1 17(q)								
Fee Fee Fee Fee Description	126 180 126 180 Submission of Information Disclosure Stmt								
103 18 203 9 Claims in excess of 20	581 40 581 40 Recording each patent assignment per property (times number of properties)								
102 84 202 42 Independent claims in excess of 3 104 280 204 140 Multiple dependent claim, if not paid	146 740 246 370 Filing a submission after final rejection (37 CFR § 1.129(a))								
109 84 209 42 ** Reissue independent claims over original patent	149 740 249 370 For each additional invention to be examined (37 CFR § 1.129(b))								
110 18 210 9 ** Reissue claims in excess of 20	179 740 279 370 Request for Continued Examination (RCE)								
and over original patent	169 900 169 900 Request for expedited examination								
SUBTOTAL (2) (\$) 306	of a design application  Other fee (specify)								
OUBTOTAL (Z)									
**or number previously paid, if greater; For Reissues, see above *Reduced by Basic Filing Fee Paid SUBTOTAL (3) (\$)									
SUBMITTED RY									

Complete (if applicable) Name (Print/Type) Registration No. (AttomeylAgent) Lin Sun-Hoffman, Ph.D. 47,983 Telephone 240-453-3628 Signature 14-Dec-01 Date

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: MERKULOV et al.

Art Unit:

Serial No. (to be assigned)

Examiner:

Filed: December 14, 2001

Atty. Docket: CL001177DIV2

For: ISOLATED HUMAN METALLOPROTEASE PROTEINS, NUCLEIC ACID MOLECULES ENCODING HUMAN PROTEASE PROTEINS, AND USES THEREOF

## Submission Of Sequence Listing Under 37 CFR § 1.821(a)

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In compliance with 37 C.F.R. § 1.821(a), applicants submit the Sequence Listing, including the paper copy of the Sequence Listing and the computer readable copy of the Sequence Listing.

In accordance with 37 C.F.R. § 1.821(f), the paper copy of the Sequence Listing and the computer readable copy of the Sequence Listing submitted herewith in the above application are the same.

It is respectfully believed that this application complies with the Sequence Listing requirements and is now in condition for processing.

Respectfully submitted,

**CELERA GENOMICS** 

Date: December 14, 2001

Lin Sun-Hoffman, Ph.D., Reg No. 47,983

Celera Genomics Corporation 45 West Gude Drive, C2-4#20 Rockville, MD 20850

Tel: 240-453-3067 Fax: 240-453-3084